Disclaimer: The material contained in these articles is provided for general information and educational purposes only. Only your healthcare professional can address concerns and questions you may have about VEXAS syndrome.
General articles & media coverage
VEXAS Syndrome — Review (nine studies, Table One)
Holly Carpenter opens up about nasty trolls amid her father's cancer diagnosis
Who should be tested for VEXAS syndrome?
VEXAS syndrome: A review of cutaneous findings and treatments in an emerging autoinflammatory disease
Recently identified inflammatory disease VEXAS syndrome may be more common than thought
A Little-Known Inflammatory Disease Is Hiding in Plain Sight
2025
Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from the FRENVEX group
Blood, 2025
View
2024
VEXAS Patient Experience Survey
Patient survey report, October 2024
View
2024
Shared and distinct mechanisms of UBA1 inactivation across different diseases
EMBO Journal (embopress.org)
View
2024
Efficacy and safety of targeted therapies in VEXAS syndrome — ARD 2024
Annals of the Rheumatic Diseases, 2024
View
2023
Serious infections in patients with VEXAS syndrome — French VEXAS registry
ARD 2023
View
2024
Skin manifestations of VEXAS Syndrome
Dermatology journal, 2024
View
2020
Somatic Mutations in UBA1 and Severe Adult Onset Autoinflammatory Disease
New England Journal of Medicine
View
2022
Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis
Blood, 2022
View
2021
Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale multicentre case series of 116 patients
British Journal of Dermatology, 2021
View
2023
Estimated Prevalence and Clinical Manifestation of UBA1 variants Associated with VEXAS Syndrome in a Clinical Population
Journal of the American Medical Association, 2023
View
2022
Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study
Blood, 2022
View
2023
Sensitivity to targeted UBA1 inhibition in a myeloid cell line model of VEXAS syndrome
Blood Advances, 2023
View
2024
VEXAS syndrome is characterized by inflammasome activation and monocyte dysregulation
Nature Communications, 2024
View
2024
Allogeneic Hematopoietic Cell Transplantation for VEXAS Syndrome: Results of a Multicenter Study of the EBMT
Blood Advances, 2024
View
Stay informed
Get VEXAS news in your inbox
Research updates, newsletters, and foundation news — no more than twice a month.